NCT03210935 French National Database of Rare Dermatological Cancers
| NCT ID | NCT03210935 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Lille |
| Condition | Adnexal Tumor of Skin |
| Study Type | OBSERVATIONAL |
| Enrollment | 9,000 participants |
| Start Date | 2015-11-24 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 9,000 participants in total. It began in 2015-11-24 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, and cutaneous adnexal carcinomas are 3 types of rare skin cancers for which much remains unknown in terms of natural behavior, prognosis, treatment and outcomes. CARADERM is a French prospective national cohort enrolling patients with either one of these 3 tumor types, whose objectives are : * to provide epidemiological, clinical and socio-economic characteristics of patients * to identify new clinical or epidemiological prognostic factors for these rare cancers * to evaluate the impact of various treatments on outcomes
Eligibility Criteria
Inclusion Criteria: * Patients with histologically confirmed Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, or cutaneous adnexal carcinoma Exclusion Criteria: * Subjects without Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, or cutaneous adnexal carcinoma * Patients refusal
Contact & Investigator
Laurent MORTIER, MD,PhD
PRINCIPAL INVESTIGATOR
University Hospital, Lille
Frequently Asked Questions
Who can join the NCT03210935 clinical trial?
This trial is open to participants of all sexes, studying Adnexal Tumor of Skin. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03210935 currently recruiting?
Yes, NCT03210935 is actively recruiting participants. Contact the research team at laurent.mortier@chru-lille.fr for enrollment information.
Where is the NCT03210935 trial being conducted?
This trial is being conducted at Dijon, France, Le Mans, France, Pierre-Bénite, France, Amiens, France and 11 additional locations.
Who is sponsoring the NCT03210935 clinical trial?
NCT03210935 is sponsored by University Hospital, Lille. The principal investigator is Laurent MORTIER, MD,PhD at University Hospital, Lille. The trial plans to enroll 9,000 participants.